Vistin Pharma (VISTN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
29 Oct, 2026Executive summary
Q3 revenue was NOK 108.4m, broadly unchanged YoY, while EBITDA was NOK 18.852m vs NOK 28.047m; record sales volume rose 13% to 1,610 MT.
Jan–Sep sales volume increased 10% to 4,710 MT, while revenue declined 6% to NOK 320.808m and EBITDA to NOK 68.234m; currency-neutral revenue was approximately flat.
A four-week Q4 maintenance stop to replace the main distillation vessel will idle both production lines and constrain quarterly production and sales.
Financial highlights
Q3 revenue was NOK 108.4m vs NOK 108.8m YoY; FX-neutral revenue increased ~7%, offset by lower average selling prices and stronger NOK.
Q3 EBITDA was NOK 18.852m vs NOK 28.047m; EBIT was NOK 12.972m vs NOK 21.344m, and net profit was NOK 10.946m vs NOK 18.525m.
Jan–Sep revenue was NOK 320.808m vs NOK 341.546m; EBITDA was NOK 68.234m vs NOK 88.536m, and net profit was NOK 46.574m vs NOK 58.694m.
Q3 operating expenses were NOK 89.5m vs NOK 80.8m, mainly reflecting higher volume and raw-material costs; salary costs benefited from no bonus accrual vs NOK 2.5m in Q3 2025.
Q3 net finance was positive NOK 0.1m vs NOK 2.4m; Jan–Sep net finance was positive NOK 8.2m vs NOK 3.7m.
Outlook and guidance
Q4 gross-margin recovery is expected as most higher-priced raw materials purchased during the Hormuz disruption have been consumed.
2027 sales volume is expected to increase from Q3 levels; management expects process fine-tuning to support the 7,000 MT target without significant CapEx.
Existing capacity is up to ~7,000 MT annually; further capacity and unit-cost improvements are under review.
Metformin demand is forecast to grow 4%–6% annually; growth, productivity and sustainability require additional CapEx, while volume growth and safety-stock plans may raise working-capital needs.
Latest events from Vistin Pharma
- Q2 2026 saw lower revenue and EBITDA but higher sales volume and strong margins, with a NOK 1 dividend paid.VISTN
Q2 2026 - Rising diabetes prevalence fuels metformin demand, supporting growth and shareholder returns.VISTN
Redeye Theme Event Diabetes presentation - Q1 2026 delivered strong sales volume, stable profit, and a dividend proposal amid supply risks.VISTN
Q1 2026 - Rising global diabetes drives metformin demand, supporting growth, dividends, and expansion plans.VISTN
DNB Carnegie Nordic SMB Conference presentation - Record 2025 revenue, sales, and profit growth, with strong margins and a higher dividend proposed.VISTN
Q4 2025 - Record EBITDA and production volume achieved amid lower revenue and strong cost control.VISTN
Q3 2024 - Record EBITDA and net profit growth in Q2 2024, with strong margins and strategic expansion.VISTN
Q2 2024 - Double-digit revenue and profit growth, high margins, and a proposed NOK 1.25 dividend.VISTN
Q1 2025 - Record EBITDA, strong margins, and higher dividends highlight robust 2024 growth outlook.VISTN
Q4 2024